BeiGene Q2 2026 Revenue Hits $1.7 Billion, Up 30%; Lifts Full-Year Guidance to $6.6-6.8 Billion
BeiGene reported net profit of $464 million for the first half of 2026, up 3.86 times year-on-year, on total revenue of $3.219 billion, an increase of 32.31%. Second-quarter net profit was $237 million, up 1.51 times, with revenue of $1.705 billion, up 29.63%. Core product Brukinsa (zanubrutinib) generated global revenue of $1.2 billion in the quarter, up 31%. The company raised its full-year 2026 revenue guidance to between $6.6 billion and $6.8 billion, with GAAP operating profit guidance of $1.0-1.1 billion and non-GAAP operating profit guidance of $1.7-1.8 billion.
BeiGene has announced its interim results for 2026. Under US Generally Accepted Accounting Principles (GAAP), the company recorded net profit of $464 million for the six months ended June 30, up 3.86 times from the same period last year, with earnings per share of $0.32. Total revenue for the period reached $3.219 billion, up 32.31% year-on-year.
In the second quarter, net profit was $237 million, up 1.51 times year-on-year, with earnings per share of $0.16. Quarterly total revenue amounted to $1.705 billion, up 29.63%. The company's core product Brukinsa (zanubrutinib) generated global revenue of $1.2 billion in the second quarter, representing an increase of 31% year-on-year.
The company raised its full-year 2026 total revenue guidance to between $6.6 billion and $6.8 billion, with the previous guidance lower bound at $6.6 billion. Full-year GAAP operating profit guidance stands at $1.0 billion to $1.1 billion, while non-GAAP operating profit guidance is set at $1.7 billion to $1.8 billion.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Pharmaceuticals, with intensity 80/100 and 85% confidence over a short term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.